Paracentesis-induced Circulatory Dysfunction: a Primer for the Interventional Radiologist

Overview

Journal Semin Intervent Radiol

Specialty Radiology

Date 2014 Sep 2

PMID 25177092

Citations 13

Authors

Aaron J Lindsay

James Burton

Charles E Ray Jr

Affiliations

Soon will be listed here.

Abstract

Paracentesis-induced circulatory dysfunction is a complication of large volume paracentesis that leads to faster reaccumulation of ascites, hyponatremia, renal impairment, and shorter survival. Knowledge of the pathophysiology, clinical presentation, diagnosis, and prevention of this condition is vital to the interventional radiologist as a valued team member in the treatment of ascites.

Citing Articles

Serum sodium level is predictive for kidney injury or hyponatremia after modest-volume paracentesis (<5 L) in Asian patients with cirrhosis: A single-centered retrospective observational study.

Aramcharoen C, Praguylertluck W, Intarasak N, Yaowmaneerat T, Kaewdech A, Chamroonkul N Medicine (Baltimore). 2025; 104(6):e41420.

PMID: 39928798 PMC: 11813013. DOI: 10.1097/MD.0000000000041420.

Drainage of ascites in cirrhosis.

Yang J, Peng Y, Zeng H, Lin X, Xu Z World J Hepatol. 2024; 16(9):1245-1257.

PMID: 39351514 PMC: 11438587. DOI: 10.4254/wjh.v16.i9.1245.

Role of albumin infusion in cirrhosis-associated complications.

Heybe M, Mehta K Clin Exp Med. 2024; 24(1):58.

PMID: 38551716 PMC: 10980629. DOI: 10.1007/s10238-024-01315-1.

Transjugular Intrahepatic Portosystemic Shunt Reductions.

Joseph A, Lopera J Semin Intervent Radiol. 2023; 40(1):44-54.

PMID: 37152796 PMC: 10159716. DOI: 10.1055/s-0043-1764410.

Large volume paracentesis of 39.5 liters chylous ascites in the setting of high-grade follicular lymphoma.

Hughes 3rd J, Bishop T, Mcloney E, Thomas S, Wessinger J Radiol Case Rep. 2022; 17(11):4276-4279.

PMID: 36124318 PMC: 9482078. DOI: 10.1016/j.radcr.2022.08.036.

References

Kuiper J, de Man R, van Buuren H . Review article: Management of ascites and associated complications in patients with cirrhosis. Aliment Pharmacol Ther. 2008; 26 Suppl 2:183-93. DOI: 10.1111/j.1365-2036.2007.03482.x. View

Planas R, Montoliu S, Belen Balleste , Rivera M, Miquel M, Masnou H . Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006; 4(11):1385-94. DOI: 10.1016/j.cgh.2006.08.007. View

Peltekian K, Wong F, Liu P, Logan A, Sherman M, Blendis L . Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol. 1997; 92(3):394-9. View

Vila M, Sola R, Molina L, Andreu M, Coll S, Gana J . Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. J Hepatol. 1998; 28(4):639-45. DOI: 10.1016/s0168-8278(98)80288-2. View

Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R . Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996; 111(4):1002-10. DOI: 10.1016/s0016-5085(96)70068-9. View

Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A . Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987; 7(1):122-8. DOI: 10.1002/hep.1840070124. View

Ryan J, Sudhir K, Jennings G, Esler M, Dudley F . Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology. 1993; 105(4):1167-72. DOI: 10.1016/0016-5085(93)90963-d. View

Hsu S, Huang H . Management of ascites in patients with liver cirrhosis: recent evidence and controversies. J Chin Med Assoc. 2013; 76(3):123-30. DOI: 10.1016/j.jcma.2012.11.005. View

Serste T, Francoz C, Durand F, Rautou P, Melot C, Valla D . Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011; 55(4):794-9. DOI: 10.1016/j.jhep.2011.01.034. View

10.

Kwok C, Krupa L, Mahtani A, Kaye D, Rushbrook S, Phillips M . Albumin reduces paracentesis-induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta-analysis. Biomed Res Int. 2013; 2013:295153. PMC: 3816020. DOI: 10.1155/2013/295153. View

11.

Singh V, Dheerendra P, Singh B, Nain C, Chawla D, Sharma N . Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008; 103(6):1399-405. DOI: 10.1111/j.1572-0241.2008.01787.x. View

12.

Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M . Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2011; 61(1):108-16. DOI: 10.1136/gutjnl-2011-300157. View

13.

Pozzi M, Osculati G, Boari G, Serboli P, Colombo P, Lambrughi C . Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology. 1994; 106(3):709-19. DOI: 10.1016/0016-5085(94)90706-4. View

14.

Sola-Vera J, Such J . Understanding the mechanisms of paracentesis-induced crculatory dysfunction. Eur J Gastroenterol Hepatol. 2004; 16(3):295-8. DOI: 10.1097/00042737-200403000-00008. View

15.

Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J . Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988; 94(6):1493-502. DOI: 10.1016/0016-5085(88)90691-9. View

16.

Singh V, Kumar R, Nain C, Singh B, Sharma A . Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol. 2006; 21(1 Pt 2):303-7. DOI: 10.1111/j.1440-1746.2006.04182.x. View

17.

Fimiani B, Guardia D, Puoti C, DAdamo G, Cioffi O, Pagano A . The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study. Eur J Intern Med. 2011; 22(6):587-90. DOI: 10.1016/j.ejim.2011.06.013. View

18.

Alessandria C, Elia C, Mezzabotta L, Risso A, Andrealli A, Spandre M . Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis. 2011; 43(11):881-6. DOI: 10.1016/j.dld.2011.06.001. View

19.

Ge P, Runyon B . The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2013; 60(3):643-53. DOI: 10.1016/j.jhep.2013.09.016. View

20.

Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B . Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut. 2002; 50(1):90-4. PMC: 1773081. DOI: 10.1136/gut.50.1.90. View